Young Joon Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Young Joon Park has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Byoung Chul Cho
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
78 shared publications - Jae Hwan Kim
Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, South Korea
78 shared publications - Min Hee Hong
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
78 shared publications - Sun Min Lim
Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
78 shared publications - Chai Young Lee
Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
39 shared publications - Christopher Daly
Regeneron Pharmaceuticals, Inc., Tarrytown, New York
39 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
An in vivo test was conducted to assess whether the NLRP3 inhibitor MCC950 suppressed the anti-cancer effects of denfivontinib treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
An in vivo test was conducted to assess whether the NLRP3 inhibitor MCC950 suppressed the anti-cancer effects of denfivontinib treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
A Regulatory T cells from multiplex IHC analysis data. Denivontinib treatment significantly decreased Treg differentiation of regulatory T cells. b The serum was obtained from the YHIM-2004 humanized mouse model and analyzed using a cytokine array. The levels of the immunosuppressive cytokines, IL-10 and IL-1RA, decreased after combination treatment. Student’s t-test, (*P<0.05, **P≤0.01).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
A Regulatory T cells from multiplex IHC analysis data. Denivontinib treatment significantly decreased Treg differentiation of regulatory T cells. b The serum was obtained from the YHIM-2004 humanized mouse model and analyzed using a cytokine array. The levels of the immunosuppressive cytokines, IL-10 and IL-1RA, decreased after combination treatment. Student’s t-test, (*P<0.05, **P≤0.01).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S17 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
Gene set enrichment analysis of five enhanced pathways among the nine pathways.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S17 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
Gene set enrichment analysis of five enhanced pathways among the nine pathways.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S16 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
The top 20 significant genes in each cancer cluster.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S16 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
The top 20 significant genes in each cancer cluster.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
Individual T-cell panels from multiplex IHC analysis. Bar size = 1.6 mm; Blue, DAPI; green, CD4 + T cells; red, CD8 + T cells; yellow, GZMB.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
Individual T-cell panels from multiplex IHC analysis. Bar size = 1.6 mm; Blue, DAPI; green, CD4 + T cells; red, CD8 + T cells; yellow, GZMB.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
Immunocytochemistry staining was performed using ImageJ software. Green, red, and yellow colors were automatically assigned.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
Immunocytochemistry staining was performed using ImageJ software. Green, red, and yellow colors were automatically assigned.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
Myeloid cell subset gating strategy for flow cytometric analysis. The definition of each subset is shown in the figure.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
Myeloid cell subset gating strategy for flow cytometric analysis. The definition of each subset is shown in the figure.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
Table S2 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
Table S2 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
PD-L1 protein expression of 5 PDX models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
PD-L1 protein expression of 5 PDX models